查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1447734

生殖器皰疹市場評估：按類型（診斷/治療）、給藥途徑（口服、注射、局部）、最終用戶（醫院藥房、零售藥房、線上藥房、其他）和地區劃分的機會和預測（2017-2031）

Genital Herpes Market Assessment, By Type [Diagnosis, Treatment], Route of Administration [Oral, Injectable, Topical], End-user [Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others], Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 225 Pages | 商品交期: 3-5個工作天內

價格

全球生殖器皰疹市場規模將從2023年的22.5億美元成長到2031年的33.9億美元，2024-2031年預測期間複合年增長率為5.24%，預計規模也將持續成長。

全球生殖器皰疹市場受到多種因素的影響。 其中包括生殖器皰疹盛行率上升、認識提高、對局部藥物的需求增加、單純皰疹病毒診斷的創新、耐阿昔洛韋單純皰疹病毒感染的發展以及對研究的更多關注。

生殖器皰疹盛行率上升是最重要的因素之一。 全世界有數百萬人患有性傳染病，而且這個數字還在持續上升。 因此，越來越需要有效的治療方法和藥物來控制症狀並阻止傳播。 對生殖器皰疹的認識不斷提高是影響市場的另一個面向。 隨著越來越多人意識到生殖器皰疹的危險和影響，對教育和預防措施的需求也隨之增加。 新療法和診斷設備研發的資金也在增加。

生殖器皰疹盛行率不斷上升

由於生殖器皰疹盛行率不斷增加，全球生殖器皰疹市場正以相當大的速度擴張。 患者數量的增加推動了治療需求，並開發了藥品、診斷和相關服務的新市場。 根據目前的基本估計，全球有超過5億人患有生殖器皰疹。 皰疹的估計盛行率隨著年齡的增長而增加，因為它是一種終生感染，而 HSV-2 的盛行率在世界衛生組織非洲區域 (AFRO) 和女性中較高。

提高意識

宣傳活動的擴大也是推動市場的主要因素之一。 隨著人們認識的提高，生殖器皰疹市場預計將穩步擴大，重點是預防、早期診斷和有效的管理技術。 隨著大眾對性傳染病，特別是生殖器皰疹的了解不斷增加，對教育、預防技術和治療方案的需求也會增加。 政府機構和衛生組織的措施也有助於教育人們，提高他們對感染的了解，並激勵他們盡快就醫。

本報告調查了全球生殖器皰疹市場，提供了市場定義和概述、市場規模趨勢和預測、各個細分市場和地區的詳細分析、行業結構以及影響市場成長的因素分析、案例研究、競爭格局、主要公司的簡介等等。

目錄

第1章研究方法

第 2 章專案範圍與定義

第 3 章執行摘要

第4章全球生殖器皰疹市場展望

  • 市場規模/預測
  • 依類型
    • 診斷
    • 處理中
  • 依給藥途徑
    • 口頭
    • 注射
    • 本地
  • 按最終用戶
    • 醫院藥房
    • 零售藥局
    • 網路藥局
    • 其他
  • 按地區
    • 北美
    • 歐洲
    • 南美洲
    • 亞太地區
    • 中東/非洲
  • 各公司的市佔率

第5章全球生殖器皰疹市場展望：依地區

  • 北美
  • 歐洲
  • 南美洲
  • 亞太地區
  • 中東/非洲

第 6 章市場映射

  • 依類型
  • 依給藥途徑
  • 按最終用戶
  • 按地區

第7章宏觀環境與產業結構

  • 需求與供給分析
  • 匯入/匯出分析
  • 價值鏈分析
  • PESTEL 分析
  • 波特五力分析

第 8 章市場動態

  • 生長促進因素
  • 抑制生長的因素（問題/抑制因素）

第 9 章監理架構與創新

  • 臨床試驗
  • 專利情況
  • 監理機關的核准
  • 創新/新興技術

第10章主要公司狀況

  • 前 5 名市場領導者的競爭矩陣
  • 前 5 位市場領導者的市場收入分析
  • 併購/合資企業（如果適用）
  • SWOT 分析（主要公司）
  • 專利分析（如果適用）

第11章價格分析

第 12 章案例研究

第13章主要公司展望

  • Bausch + Lomb Corporation
  • GlaxoSmithKline plc
  • Viatris Inc.
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Dr. Reddy's Laboratories, Ltd.
  • Abbott Laboratories
  • Pfizer Inc.
  • Sun Pharmaceuticals Industries Ltd.
  • Fresenius SE & Co KGaA

第 14 章策略建議

第15章關於我們公司/免責聲明

Product Code: MX11141

Global genital herpes market is projected to witness a CAGR of 5.24% during the forecast period, 2024-2031, growing from USD 2.25 billion in 2023 to USD 3.39 billion in 2031. The global genital herpes market is shaped by various factors. These include an increase in the prevalence of genital herpes, a rise in awareness, increasing demand for topical medications, innovations in HSV diagnosis, development of acyclovir-resistant HSV infections, and increased focus on research.

The rise in the prevalence of genital herpes is one of the most important factors. Millions of people are afflicted with STDs globally, and the number of cases is rising. Consequently, there is an increasing need for efficient therapies and drugs to control the signs and stop the spread. Growing awareness of genital herpes is another aspect influencing the global genital herpes market. The need for education and preventative measures is growing as more people are becoming aware of the dangers and repercussions of genital herpes. Funding for research and development of novel therapies and diagnostic instruments has increased.

The market for topical treatments for genital herpes is expanding due to the rising consumer demand propelling the growth of the global genital herpes market. Many patients choose topical therapies as they are simple to use and may be administered directly to the area that is affected. As a result, new topical drugs with reduced side effects and increased effectiveness have been developed. The global genital herpes market is being shaped by developments in HSV diagnosis. More rapid and accurate viral detection is possible with the development of new diagnostic techniques, which will enable early diagnosis and treatment.

The emergence of HSV infections resistant to acyclovir is another reason propelling the expansion of global genital herpes market. Novel and creative treatments are required to control the infection as the virus gets more resistant to conventional ones. Lastly, the market for genital herpes is expanding due to the greater emphasis on research. The likelihood of discovering novel treatments and cures increases with increased funds and resources allocated to research and development. These variables are influencing the global genital herpes market and propelling business expansion.

For instance, in September 2023, the U.S. National Institutes of Health laid out a strategic plan for Herpes Vaccine Research. The plan outlines a framework for HSV research with four strategic priorities, from expanding the understanding of the biology, pathophysiology, and epidemiology of HSV, quickening the pace of research to enhance HSV diagnosis, refining treatment approaches while pursuing a cure, and promoting research to prevent HSV infection.

Increase in the Prevalence of Genital Herpes

The global genital herpes market is expanding at a significant rate due to the increasing prevalence of genital herpes. The growing number of cases drives the treatment demand, which opens new markets for pharmaceuticals, diagnostics, and related services. Based on current estimates, over 500 million individuals globally suffer from genital herpes. The estimated prevalence of herpes rose with age as it is a lifetime infection and WHO African Region (AFRO) and women had a higher prevalence of HSV-2. Biologic vulnerability to HIV and HSV-2 is higher in women. Women in the WHO Africa Region are most likely to be exposed to HIV and have high HSV-2 prevalence, which increases their chance of contracting HIV and has detrimental effects on their health and well-being. Herpes symptoms can be more severe and frequent among those who have both HSV-2 and HIV, or who are coping with other illnesses that affect their immune systems.

Rise in Awareness

The expansion of awareness campaigns is one of the major factors driving the global genital herpes market. The market for genital herpes is anticipated to expand steadily as awareness grows and with a focus on prevention, early diagnosis, and efficient management techniques. The need for education, prevention techniques, and treatment choices increases as public knowledge of STDs, particularly genital herpes, rises. Due to increased awareness, appropriate behavior and a proactive attitude towards sexual health are encouraged, which propels the expansion of global genital herpes market. Governmental and healthcare organizations' initiatives help educate people and become more informed about infection and motivated them to seek medical attention as soon as possible.

The United Nations Fund for Population Activities (UNFPA) introduced "Just Ask!" in July 2023 as a chatbot to raise awareness of sexual and reproductive health and rights in India. It is a digital engagement platform powered by artificial intelligence (AI) designed to educate teenagers and young adults about their rights and sexual and reproductive health. Experts from UNFPA on sexual and reproductive health created the chatbot, which was released in close cooperation with the Madhya Pradesh government's Department of Public Health and Family Welfare and the National Health Mission (NHM).

Increasing Demand for Topical Medications

The growing demand for topical medications is increasing the market size of genital herpes globally. Herpes simplex virus infections of the skin, mucous membranes, and genitals are treated with topical medicine. Due to their advantages over oral treatments, topical therapies are becoming more and more popular in the global genital herpes market. Topical drugs are easier to apply than tablets or capsules since they are typically available in cream, gel, or ointment forms. Topical formulations are appealing to patients and healthcare professionals due to benefits such as convenience and ease of administration. Topical treatments can be applied directly to the lesion or affected area, offering faster relief and possibly fewer side effects than oral medications, which must first travel through the digestive system before reaching the infection site.

For instance, Zydus Lifesciences declared in March 2023 that has received the US Food and Drug Administration's (USFDA) final approval for Acyclovir Cream. Acyclovir is a member of the antiviral drug class. Acyclovir lotion is used to treat genital herpes.

Innovations in HSV Diagnosis

The global genital herpes market is undergoing a revolution due to the advancements in diagnosis techniques that are greatly improving patient results. The developments improve the effectiveness of diagnosis and the management and control of diseases, which in turn improves patient care and quality of life. Early diagnosis of HSV infections is now possible due to the development of faster and more reliable testing techniques, which lower the risk of transmission and enable timely treatment commencement. Innovative diagnostic technologies are boosting demand for genital herpes testing and treatment options, influencing the future landscape of the market by helping healthcare providers diagnose HSV infections more accurately.

The Truenat HSV 1/2 herpes test was introduced in January 2023 by Molbio Diagnostics. Approved by the Central Drug Standard Control Organisation (CDSCO), it is an RT-PCR test for herpes diagnosis that uses chips. There is no need for additional setup or equipment because the test is compatible with the current Truelab infrastructure.

Growing European Market

The global genital herpes market is growing significantly in Europe for several reasons. Large healthcare budgets are allotted in nations like Germany and the United Kingdom, allowing for investments in R&D and access to cutting-edge genital herpes therapies. Increased knowledge and understanding of genital herpes in these nations motivate people to seek prompt medical care, which fuels demand for genital herpes treatments and aids in the growth of the global genital herpes market. Furthermore, Europe's strict regulatory environment encourages market expansion. It is anticipated that the region will continue to grow steadily due to its favorable high level of awareness of cutting-edge STD treatment alternatives and patient demographics.

AiCuris, a German clinical-stage biopharmaceutical company, announced in July 2023 that it was concentrating on producing Pritelivir, a treatment for acyclovir-resistant herpes simplex virus infections, in phase 3 of development, to further strengthen its pipeline for infectious diseases.

Future Market Scenario (2024 - 2031F)

Social media and digital health platforms that educate young people about sexual and reproductive health are becoming more and more popular, which is contributing to the growth of the worldwide genital herpes market.

Robotic process automation is increasingly being used in the manufacturing of drugs used for treatment of genital herpes which will drive the global genital herpes market in the future.

AI-based digital diagnostic tools are increasingly being used for screening and diagnosing STIs driving the global genital herpes market.

The rise in the global genital herpes market will be fueled by changing lifestyles, as higher infection rates will lead to increased need for treatment.

Key Players Landscape and Outlook

Cooperation among academic institutions, healthcare providers, and other industry players is common in global genital herpes market. Small and medium-sized businesses are working together to make use of each other's experience, gain access to more resources, and broaden their reach in the market. These businesses have a competitive edge due to their capacity to introduce novel, efficient treatments to the market. Collaborations aid in the creation of novel antiviral medications, therapeutic vaccinations, and creative delivery methods, among other forms of new medical treatments. Patents and intellectual property rights give businesses protection and exclusivity for their creative treatment ideas, which makes them competitive.

A collaborative agreement to develop, produce, and market live vaccines against herpes simplex viruses (HSV-1 and HSV-2) in China was announced in October 2023 by Shenzhen Mellow Hope Pharm Industrial Co., Ltd. (MH) and Rational Vaccines (RVx).

Table of Contents

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global Genital Herpes Market Outlook, 2017-2031F

  • 4.1.Market Size & Forecast
    • 4.1.1.By Value
    • 4.1.2.By Volume
  • 4.2.By Type
    • 4.2.1.Diagnosis
    • 4.2.2.Treatment
      • 4.2.2.1.Acyclovir
      • 4.2.2.2.Famciclovir
      • 4.2.2.3.Valacyclovir
      • 4.2.2.4.Others
  • 4.3.By Route of Administration
    • 4.3.1.Oral
    • 4.3.2.Injectable
    • 4.3.3.Topical
  • 4.4.By End-user
    • 4.4.1.Hospital Pharmacies
    • 4.4.2.Retail Pharmacies
    • 4.4.3.Online Pharmacies
    • 4.4.4.Others
  • 4.5.By Region
    • 4.5.1.North America
    • 4.5.2.Europe
    • 4.5.3.Asia-Pacific
    • 4.5.4.South America
    • 4.5.5.Middle East and Africa
  • 4.6.By Company Market Share (%), 2023

5.Global Genital Herpes Market Outlook, By Region, 2017-2031F

  • 5.1.North America*
    • 5.1.1.Market Size & Forecast
      • 5.1.1.1.By Value
      • 5.1.1.2.By Volume
    • 5.1.2.By Type
      • 5.1.2.1.Diagnosis
      • 5.1.2.2.Treatment
      • 5.1.2.2.1.Acyclovir
      • 5.1.2.2.2.Famciclovir
      • 5.1.2.2.3.Valacyclovir
      • 5.1.2.2.4.Others
    • 5.1.3.By Route of Administration
      • 5.1.3.1.Oral
      • 5.1.3.2.Injectable
      • 5.1.3.3.Topical
    • 5.1.4.By End-user
      • 5.1.4.1.Hospital Pharmacies
      • 5.1.4.2.Retail Pharmacies
      • 5.1.4.3.Online Pharmacies
      • 5.1.4.4.Others
    • 5.1.5.United States*
      • 5.1.5.1.Market Size & Forecast
      • 5.1.5.1.1.By Value
      • 5.1.5.1.2.By Volume
      • 5.1.5.2.By Type
      • 5.1.5.2.1.Diagnosis
      • 5.1.5.2.2.Treatment
      • 5.1.5.2.2.1.Acyclovir
      • 5.1.5.2.2.2.Famciclovir
      • 5.1.5.2.2.3.Valacyclovir
      • 5.1.5.2.2.4.Others
      • 5.1.5.3.By Route of Administration
      • 5.1.5.3.1.Oral
      • 5.1.5.3.2.Injectable
      • 5.1.5.3.3.Topical
      • 5.1.5.4.By End-user
      • 5.1.5.4.1.Hospital Pharmacies
      • 5.1.5.4.2.Retail Pharmacies
      • 5.1.5.4.3.Online Pharmacies
      • 5.1.5.4.4.Others
    • 5.1.6.Canada
    • 5.1.7.Mexico

All segments will be provided for all regions and countries covered

  • 5.2.Europe
    • 5.2.1.Germany
    • 5.2.2.France
    • 5.2.3.Italy
    • 5.2.4.United Kingdom
    • 5.2.5.Russia
    • 5.2.6.Netherlands
    • 5.2.7.Spain
    • 5.2.8.Turkey
    • 5.2.9.Poland
  • 5.3.Asia-Pacific
    • 5.3.1.India
    • 5.3.2.China
    • 5.3.3.Japan
    • 5.3.4.Australia
    • 5.3.5.Vietnam
    • 5.3.6.South Korea
    • 5.3.7.Indonesia
    • 5.3.8.Philippines
  • 5.4.South America
    • 5.4.1.Brazil
    • 5.4.2.Argentina
  • 5.5.Middle East & Africa
    • 5.5.1.Saudi Arabia
    • 5.5.2.UAE
    • 5.5.3.South Africa

6.Market Mapping, 2023

  • 6.1.By Type
  • 6.2.By Route of Administration
  • 6.3.By End-user
  • 6.4.By Region

7.Macro Environment and Industry Structure

  • 7.1.Demand Supply Analysis
  • 7.2.Import Export Analysis
  • 7.3.Value Chain Analysis
  • 7.4.PESTEL Analysis
    • 7.4.1.Political Factors
    • 7.4.2.Economic System
    • 7.4.3.Social Implications
    • 7.4.4.Technological Advancements
    • 7.4.5.Environmental Impacts
    • 7.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5.Porter's Five Forces Analysis
    • 7.5.1.Supplier Power
    • 7.5.2.Buyer Power
    • 7.5.3.Substitution Threat
    • 7.5.4.Threat from New Entrant
    • 7.5.5.Competitive Rivalry

8.Market Dynamics

  • 8.1.Growth Drivers
  • 8.2.Growth Inhibitors (Challenges and Restraints)

9.Regulatory Framework and Innovation

  • 9.1.Clinical Trials
  • 9.2.Patent Landscape
  • 9.3.Regulatory Approvals
  • 9.4.Innovations/Emerging Technologies

10.Key Players Landscape

  • 10.1.Competition Matrix of Top Five Market Leaders
  • 10.2.Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3.Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4.SWOT Analysis (For Five Market Players)
  • 10.5.Patent Analysis (If Applicable)

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

  • 13.1.Bausch + Lomb Corporation
    • 13.1.1.Company Details
    • 13.1.2.Key Management Personnel
    • 13.1.3.Products & Services
    • 13.1.4.Financials (As reported)
    • 13.1.5.Key Market Focus & Geographical Presence
    • 13.1.6.Recent Developments
  • 13.2.GlaxoSmithKline plc
  • 13.3.Viatris Inc.
  • 13.4.Novartis AG
  • 13.5.Teva Pharmaceutical Industries Ltd.
  • 13.6.Dr. Reddy's Laboratories, Ltd.
  • 13.7.Abbott Laboratories
  • 13.8.Pfizer Inc.
  • 13.9.Sun Pharmaceuticals Industries Ltd.
  • 13.10.Fresenius SE & Co KGaA

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14.Strategic Recommendations

15.About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1.Global Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 2.Global Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 3.Global Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 4.Global Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 5.Global Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 6.Global Genital Herpes Market Share (%), By Region, 2017-2031F
  • Figure 7.North America Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 8.North America Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 9.North America Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 10.North America Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 11.North America Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 12.North America Genital Herpes Market Share (%), By Country, 2017-2031F
  • Figure 13.United States Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 14.United States Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 15.United States Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 16.United States Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 17.United States Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 18.Canada Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 19.Canada Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 20.Canada Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 21.Canada Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 22.Canada Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 23.Mexico Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 24.Mexico Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 25.Mexico Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 26.Mexico Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 27.Mexico Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 28.Europe Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 29.Europe Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 30.Europe Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 31.Europe Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 32.Europe Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 33.Europe Genital Herpes Market Share (%), By Country, 2017-2031F
  • Figure 34.Germany Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 35.Germany Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 36.Germany Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 37.Germany Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 38.Germany Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 39.France Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 40.France Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 41.France Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 42.France Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 43.France Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 44.Italy Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 45.Italy Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 46.Italy Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 47.Italy Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 48.Italy Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 49.United Kingdom Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 50.United Kingdom Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 51.United Kingdom Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 52.United Kingdom Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 53.United Kingdom Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 54.Russia Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 55.Russia Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 56.Russia Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 57.Russia Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 58.Russia Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 59.Netherlands Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 60.Netherlands Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 61.Netherlands Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 62.Netherlands Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 63.Netherlands Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 64.Spain Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 65.Spain Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 66.Spain Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 67.Spain Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 68.Spain Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 69.Turkey Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 70.Turkey Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 71.Turkey Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 72.Turkey Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 73.Turkey Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 74.Poland Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 75.Poland Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 76.Poland Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 77.Poland Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 78.Poland Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 79.South America Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 80.South America Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 81.South America Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 82.South America Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 83.South America Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 84.South America Genital Herpes Market Share (%), By Country, 2017-2031F
  • Figure 85.Brazil Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 86.Brazil Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 87.Brazil Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 88.Brazil Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 89.Brazil Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 90.Argentina Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 91.Argentina Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 92.Argentina Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 93.Argentina Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 94.Argentina Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 95.Asia-Pacific Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 96.Asia-Pacific Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 97.Asia-Pacific Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 98.Asia-Pacific Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 99.Asia-Pacific Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 100.Asia-Pacific Genital Herpes Market Share (%), By Country, 2017-2031F
  • Figure 101.India Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 102.India Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 103.India Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 104.India Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 105.India Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 106.China Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 107.China Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 108.China Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 109.China Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 110.China Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 111.Japan Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 112.Japan Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 113.Japan Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 114.Japan Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 115.Japan Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 116.Australia Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 117.Australia Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 118.Australia Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 119.Australia Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 120.Australia Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 121.Vietnam Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 122.Vietnam Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 123.Vietnam Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 124.Vietnam Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 125.Vietnam Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 126.South Korea Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 127.South Korea Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 128.South Korea Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 129.South Korea Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 130.South Korea Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 131.Indonesia Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 132.Indonesia Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 133.Indonesia Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 134.Indonesia Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 135.Indonesia Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 136.Philippines Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 137.Philippines Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 138.Philippines Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 139.Philippines Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 140.Philippines Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 141.Middle East & Africa Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 142.Middle East & Africa Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 143.Middle East & Africa Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 144.Middle East & Africa Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 145.Middle East & Africa Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 146.Middle East & Africa Genital Herpes Market Share (%), By Country, 2017-2031F
  • Figure 147.Saudi Arabia Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 148.Saudi Arabia Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 149.Saudi Arabia Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 150.Saudi Arabia Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 151.Saudi Arabia Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 152.UAE Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 153.UAE Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 154.UAE Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 155.UAE Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 156.UAE Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 157.South Africa Genital Herpes Market, By Value, in USD Billion, 2017-2031F
  • Figure 158.South Africa Genital Herpes Market, By Volume, in Million Units, 2017-2031F
  • Figure 159.South Africa Genital Herpes Market Share (%), By Type, 2017-2031F
  • Figure 160.South Africa Genital Herpes Market Share (%), By Route of Administration, 2017-2031F
  • Figure 161.South Africa Genital Herpes Market Share (%), By End-user, 2017-2031F
  • Figure 162.By Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 163.By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 164.By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 165.By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023